Hyfinity Investments

Immunowake is a biotechnology company dedicated to developing innovative therapies for patients who do not respond to conventional immunotherapies. The company is focused on creating a universal cancer vaccine that aims to generate safer and more effective bi-specific antibodies. By activating the body’s immune system, particularly antigen-specific T-cells, Immunowake seeks to enhance the ability to identify and eliminate cancer cells. This approach not only aims to improve treatment outcomes for patients with limited options but also strives to reduce toxicity associated with existing therapies while maintaining significant anti-tumor efficacy.

InxMed (Nanjing) Co., Ltd. is a clinical-stage biotechnology company based in Nanjing, China, with additional offices in Beijing, Shanghai, and Sydney, Australia. Founded in 2018, InxMed focuses on the research and development of innovative treatment options for patients, particularly in oncology. The company is working on several drug candidates, including IN10018, a selective ATP-competitive focal adhesion kinase (FAK) small molecule inhibitor for cancer treatment, INX0001 for liver and colorectal cancer, and various other programs such as IN30101. By emphasizing a deep understanding of disease biology and pharmacology, InxMed aims to develop "Best-in-Disease Combination" medicines that address unmet medical needs.

Carcell Biopharma is a pre-clinical biotechnology company that specializes in the development of advanced cell and gene therapy products. The company focuses on creating biopharmaceutical platforms that utilize engineered red blood cells for immune regulation and non-viral vector gene delivery through lipid nanoparticles. By employing an innovative cross-border business model, Carcell Biopharma aims to accelerate the discovery and development of next-generation therapies in this rapidly evolving field.

Oculis is a clinical-stage biotechnology company dedicated to developing innovative topical treatments for ophthalmic diseases affecting both the anterior and posterior segments of the eye. Founded in 2003 and headquartered in Reykjavik, Iceland, Oculis utilizes a unique drug delivery platform that enhances drug absorption through a novel technique, enabling effective treatment of conditions such as diabetic macular edema, uveitis, chronic dry eye syndrome, glaucoma, and diabetic retinopathy with simple eye drops. This approach allows for non-invasive treatment of diseases at the back of the eye, traditionally requiring more complex methods, while also reducing the frequency of applications needed for anterior eye conditions. Oculis is committed to improving patient outcomes and enhancing the quality of life for individuals with vision-related health issues.

Elpiscience Biopharmaceuticals Co., Ltd. operates as an immunology company that develops immunotherapies to treat cancer. The company is based in Pudong, China with an additional office in Suzhou, China.

Beijing Surgerii Technology Co., Ltd. specializes in the research, development, production, and sale of minimally invasive surgical robot systems in China. Founded in 2014 and based in Beijing, the company focuses on innovative technologies, particularly the next generation of flexible continuum robotic arms. Surgerii Technology aims to transform clinical practices through its single-hole and porous laparoscopic robot systems, enhancing the standard of care in minimally invasive surgeries. With a commitment to independent research and development, the company leverages its expertise in system design and integration to advance the medical equipment industry in China.

Hexaell Biotechnology Co., Ltd is a start-up company pioneering in stem cell and artificial organ. The disruptive technologies were original published in "Nature. 475(7356):386-9" and "Cell Stem Cell. 14(3):370-84" from Chinese Academy of Sciences. Hexaell Biotechnology had licensed iHep and HiHep technologies from Chinese Academy of Sciences and developed medical devices of bio-artificial liver to replace liver function of human and cure liver failure diseases. Hexaell has finished pilot clinical studies in 6 liver failure patients in leading hepatopathy centers in China.

Provider of medical and health administration services. The company's services include rational drug use management services that provides a complete set of clinical rational drug use management solutions based on real world clinical prescription data, enabling medical institutions to make better prescription decisions.